Is anyone else getting nervous that sites are taking this long to set up and the fact we don’t have a ton of infusions yet? I really do like the company but we don’t have any revenue coming in yet so that makes me a little nervous. Thoughts?
Never meant to be a blockbuster and only a filler until other drug from pipeline comes out. Then it won't require a salesforce because of the small niche it may somehow still fill. You are in the definite minority if you like this company, as most feel it is a very UBER metrics based company. Told one story about culture in the interview and it is completely different once onboard. It's unfortunate that many employees at Sage have never worked for a real biotech company with a great culture and they would know the difference. You can't be happy with the money, unless you never launch a drug before. The quarterly bonus payout is extremely low for a brand new drug launch and clearly that won't change. Most people only join companies with a new drug launch because that is the small window of time where you can make big money, but that won't happen here. The bonus potential here is no different than any common pharmaceutical company.
I have 3 infusions and 2 REMS sites so far. Lots of work but the foundation is paying off baby! Time to get paid!
Folks at corporate walk around looking to see what brand of gold watch each other are wearing from selling the stock. Just buying time for the big payout from a buyout. Very funny and sad to watch "LOL".
Precisely. The bonus isn't generous at all. This is the time when all startups give a very generous payout generally for the first year as this is the most difficult and critical time of a launch. The current payout is an embarrassment. Most would never have come here for a low payout like this.
The KAMs just celebrated 1 year. Most areas have 1 or no soc. My KAM blows. 12 months and 1 SOC to show for it? Guess my RBD picked a real winner eh?
Yes, exactly! And now the TBS's are the driving force in making the SOC's happen. My KAM is useless. Absolutely useless. I provide all the connections. What is sick is the inequality of the pay! TBS's do all the work and get paid 40k-50K less. This company needs to wisen up.
No, they about nailed it with the comment. KAMS do jack shit. Won't really be needed once 217 comes in play.
“Equities analysts expect SAGE Therapeutics Inc (NASDAQ:SAGE) to post sales of $3.96 million for the current fiscal quarter, Zacks reports.” So what’s that...about 100-120 patients, tops? That’s assuming vials have been administered and not simply supply chain. So...maybe 70 patients?
